Cowen: Emergent Ventures operates at two percent overhead without losing money
Tyler Cowen · Reviving a Culture of Innovation with Tyler Cowen · Joe Lonsdale · Feb 16, 2022 · at 22:22
Economist Tyler Cowen describes the low-overhead operating model of his grant and fellowship program, Emergent Ventures, to Joe Lonsdale.
0:00 / 0:03exact quote · 3.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We do this all at overhead of two percent without losing money.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Tyler Cowen
Cowen: University of Virginia lobbies regulators to block GMU degree programs
“To create a new course, I actually need approval through a committee that is attached to the state of Virginia and exists in Richmond... And furthermore, like University of Virginia, our competitor will lobby that committee not to approve like a new degree pro…”
Cowen: Men underestimate the smartest women by compressing female intelligence distributions
“And then when it comes to intelligence, men compress the distribution of female intelligence. So the smartest women are smarter than men think they are. Actually other women are better at judging the smartness of those women.”
Cowen: Men undervalue smart women by projecting male variance in conscientiousness
“Women on average are more conscientious than men, and men have a higher variance of conscientiousness. So the least conscientious men wreak more destruction and havoc, right? So women have lower variance of conscientiousness. That means if you find a smart wom…”
Cowen: It is plausible for young people today to live to 130
“And the notion that a young person today might live to be 130 is not at all absurd. So I'm very bullish on the science.”
Cowen: Biomedical companies are poor investments because value accrues to consumers
“I'm not necessarily bullish on biomedical companies as vehicles for earning money. A lot of regulation, sales in bio, healthcare arena can be very tough and very labor intensive. So maybe more of the gains accrue to consumers than is the case in a lot of secto…”